X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the commercialization of an investigational osteoarthritis (OA) therapy, VOLT01 (zoledronic acid), a patented novel combination drug, in the Middle East and Africa (MEA) region, excluding South Africa.
Lead Product(s): Zoledronic Acid Derivative
Therapeutic Area: Musculoskeletal Product Name: VOLT01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Levolta Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2023
Details:
Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.
Lead Product(s): Telavancin Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: Vibativ
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Cumberland Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 31, 2022
Details:
Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Glaricon
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2021
Details:
Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine, mRNA-1273 in Saudi Arabia. The agreement also gives Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future.
Lead Product(s): mRNA-1273
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
